Nothing Special   »   [go: up one dir, main page]

AU4327300A - Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension - Google Patents

Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Info

Publication number
AU4327300A
AU4327300A AU43273/00A AU4327300A AU4327300A AU 4327300 A AU4327300 A AU 4327300A AU 43273/00 A AU43273/00 A AU 43273/00A AU 4327300 A AU4327300 A AU 4327300A AU 4327300 A AU4327300 A AU 4327300A
Authority
AU
Australia
Prior art keywords
compositions
methods
vascular disease
pulmonary hypertension
peripheral vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43273/00A
Inventor
Michael D. Bentley
Martine Rothblatt
Robert Shorr
Xuan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of AU4327300A publication Critical patent/AU4327300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0075Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
    • C07C405/0083Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU43273/00A 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension Abandoned AU4327300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12725499P 1999-03-31 1999-03-31
US12725599P 1999-03-31 1999-03-31
US60127254 1999-03-31
US60127255 1999-03-31
PCT/US2000/008240 WO2000057701A1 (en) 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Publications (1)

Publication Number Publication Date
AU4327300A true AU4327300A (en) 2000-10-16

Family

ID=26825478

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43273/00A Abandoned AU4327300A (en) 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Country Status (7)

Country Link
EP (1) EP1164846A1 (en)
JP (1) JP2003523935A (en)
KR (1) KR20020012169A (en)
CN (1) CN1354622A (en)
AU (1) AU4327300A (en)
CA (1) CA2359652A1 (en)
WO (1) WO2000057701A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
CA2959852A1 (en) 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
KR101161889B1 (en) * 2003-12-16 2012-07-02 유나이티드 쎄러퓨틱스 코포레이션 Use of treprostinil to treat and prevent ischemic lesions
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
AU2006219152B2 (en) * 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases
BR112014003240A2 (en) * 2011-08-12 2017-03-01 Ascendis Pharma As sustained release prostacyclin composition
KR101997939B1 (en) 2011-08-12 2019-07-08 아센디스 파마 에이에스 Carrier-linked treprostinil prodrugs
JP6542128B2 (en) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド Treprostinil Prodrugs
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
JP2016516693A (en) 2013-03-15 2016-06-09 ユナイテッド セラピューティクス コーポレイション Salt of treprostinil
KR102238501B1 (en) 2013-03-25 2021-04-08 유나이티드 세러퓨틱스 코오포레이션 Process of making prostacyclin compounds with linker thiol and pegylated forms
DK3060041T3 (en) * 2013-10-25 2021-03-22 Insmed Inc PROSTACYCLINE COMPOUNDS
JP2017517550A (en) 2014-06-13 2017-06-29 ユナイテッド セラピューティクス コーポレイション Treprostinil preparation
WO2016064764A1 (en) 2014-10-20 2016-04-28 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
AU2017361521B2 (en) 2016-11-21 2020-08-27 Bruker Spatial Biology, Inc. Chemical compositions and methods of using same
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2022546314A (en) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション Treprostinil prodrug
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
EP4161909A1 (en) 2020-06-09 2023-04-12 United Therapeutics Corporation Fumaryl diketopiperidine prodrugs of treprostinil
CN117062605A (en) 2020-12-14 2023-11-14 联合治疗公司 Methods of treating diseases using treprostinil prodrugs
JP2024510930A (en) 2021-03-03 2024-03-12 ユナイテッド セラピューティクス コーポレイション A dry powder composition of treprostinil and its prodrugs and further comprising (E)-3,6-bis[4-(N-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (FDKP) dry powder composition
KR20240141319A (en) 2022-02-08 2024-09-26 유나이티드 쎄러퓨틱스 코포레이션 Treprostinil iloprost combination therapy
US20240287105A1 (en) 2023-01-19 2024-08-29 United Therapeutics Corporation Treprostinil analogs and related methods of making and using

Also Published As

Publication number Publication date
JP2003523935A (en) 2003-08-12
EP1164846A1 (en) 2002-01-02
KR20020012169A (en) 2002-02-15
WO2000057701A1 (en) 2000-10-05
CN1354622A (en) 2002-06-19
CA2359652A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
AU4327300A (en) Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU5963900A (en) Muteins of bilin-binding protein
AUPR638101A0 (en) Composition and method for treatment of disease
AU2268401A (en) Novel succinate compounds, compositions and methods of use and preparation
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
AUPR101600A0 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU1878201A (en) Composition for the treatment of damaged tissue
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AUPP870999A0 (en) Method of treatment of equine disease
AU7670700A (en) Method for improving the stay-on properties of cosmetic compositions
AU4450100A (en) 225Ac-heha and related compounds, methods of synthesis and methods of use
AU3757200A (en) Treatment of pulmonary hypertension
AU5553200A (en) Process for the preparation of paroxetine and structurally related compounds
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU4034800A (en) Novel compositions and methods for prevention and treatment of protozoal disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase